April 17, 2025

In Case You Missed It: Abstracts on Novel Therapies in Gastrointestinal Cancers

Four noteworthy studies from the 2025 ASCO Gastrointestinal Cancers Symposium, each shedding new light on emerging therapeutic approaches for patients with advanced gastric, hepatocellular, and colore...

The ASCO Post

April 17, 2025

How Does Medicaid Expansion Affect Access to Care in Patients With NSCLC?

Medicaid expansion was associated with a 2.8% increase in lung cancer surgeries performed and a 2.1% increase in surgeries completed within 90 days of diagnosis at high-volume hospitals.

The ASCO Post

April 17, 2025

Poor Agreement Reported Among Diagnostic Tests for Breast Cancer–Related Lymphedema

There appears to be low to moderate agreement among various diagnostic tests for breast cancer–related lymphedema.

The ASCO Post

April 17, 2025

Advanced Esophageal Cancer: NOTCH1 Mutation and Efficacy of Tislelizumab

“Although multiple agents targeting PD-1 have been approved as second-line treatment for esophageal squamous cell carcinoma, only a fraction of patients derive long-term survival. Hence, reliable pred...

The ASCO Post

April 17, 2025

Renowned Breast Cancer Physician-Scientist Hope S. Rugo, MD, FASCO, to Lead Women’s Cancers Program at City of Hope

She will lead and enhance women’s cancers research and clinical care across the enterprise, expand clinical trials and translational research, and standardize cancer care to achieve superior patient o...

The ASCO Post

April 16, 2025

Novel Drug/Device Combination May Improve Outcomes in Metastatic Uveal Melanoma

Researchers have examined whether percutaneous hepatic perfusion using a melphalan hepatic delivery system may be an effective treatment option in patients with unresectable uveal melanoma that has me...

The ASCO Post

April 16, 2025

Can ctDNA Monitoring Help to Predict Melanoma Recurrence?

A new report shows how droplet digital polymerase chain reaction assays focusing on monitoring the most common mutations in the genetic code in melanoma cells—BRAF V600E and BRAF V600K—may help to pre...

The ASCO Post

April 16, 2025

Germline Variants May Impact Unique Nature of a Patient’s Cancer, Study Shows

Research into germline genetic variants has identified ways that an individual’s genetic makeup can shape the biology of their cancer. The report, published in Cell, shows how these findings could pot...

The ASCO Post

April 16, 2025

Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

The French phase II PANACHE01-PRODIGE48 trial investigated the feasibility and efficacy of neoadjuvant mFOLFIRINOX and FOLFOX in patients with resectable pancreatic adenocarcinoma.

The ASCO Post